Prevalencia de dislipemia y riesgo cardiovascular elevado en pacientes con artritis reumatoide

Palabras clave: artritis reumatoidea, riesgo cardiovascular, dislipemia Abstract Prevalence of dyslipidemia and elevated cardiovascular risk in patients with rheumatoid arthritis. The objectives of this study were to compare the frequency of dyslipidemia (DLP) and the elevated cardiovascular risk between rheumatoid arthritis (RA) patients and a control group, to identify disease-related factors associated with the presence of DLP and to estimate the frequency of RA patients receiving treatment for DLP. This is a cross sectional study that included 409 RA patients and 624 controls. Cardiovascular (CV) risk was determined using the Framingham score, National Cholesterol Education Program (NCEP) and the Systematic Coronary Risk Evaluation (SCORE) adapted versions according to the European League Against Rheumatism (EULAR)�guidelines.�DLPwasdefinedaccordingtotheAdultTreatmentPanelIII�(ATPIII).�ThefrequencyofCV� riskwassimilarinRApatientsandcontrols,�exceptwhenNCEP-EULARadaptedversionforRAwasapplied�(7%� vs.�2%;�p�=�0.00002).�A�43%�ofpatientsand�47%�ofcontrolshadDLP�(p�=�0.15).�RApatientswithDLPtended� tohaveextra-articularmanifestationsmorefrequently�(36%�vs.�24%;�p�=�0.01)�andhighererythrocytesedimenta- tion rate (ESR) (21 (13-35) vs.�18�(10-30)�mm;�p�=�0.003).�RApatientstreatedforDLPvariedbetween�11%�and� 32%�accordingtothedefinitionused.�PatientswithRAshowedanelevatedCVriskonlywhentheNCEP-EULAR� definitionwasused.�AmongRApatients,�thosewithhigherESRandthepresenceofextra-articularmanifestations � were more likely to show DLP. The vast majority of patients were not receiving treatment for DLP.